Publications by authors named "C Tcherakian"

Article Synopsis
  • Conventional immunosuppressants are not effective for treating asthma related to Eosinophilic Granulomatosis with Polyangiitis (EGPA).
  • Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), has shown promise in improving asthma symptoms in patients with severe refractory EGPA-related asthma.
  • Despite improvements in symptoms and asthma control, there are concerns about potential rebound eosinophilia and related complications due to TSLP inhibition, as observed in similar treatments.
View Article and Find Full Text PDF
Article Synopsis
  • - The French RAMSES study compared severe asthma patients managed in tertiary referral centres (TRCs) versus secondary care centres (SCCs) to understand differences in patient characteristics and care practices.
  • - A total of 2046 patients were included: 73.4% from TRCs and 26.6% from SCCs; key findings showed that TRC patients had more comorbidities but lower blood eosinophil counts and benefited more from educational programs and in-depth investigations.
  • - The study concluded that asthma care trajectories and patient phenotypes varied significantly between TRCs and SCCs, emphasizing the need for standardized approaches to managing severe asthma.
View Article and Find Full Text PDF

Chronic Granulomatosis Disease (CGD) is an inherited immune deficiency due to a mutation in the genes coding for the subunits of the NADPH oxidase enzyme that affects the oxidative capacity of phagocytic cells. It is characterized by increased susceptibility to bacterial and fungal infections, particularly Aspergillus, as well as complications associated with hyperinflammation and granulomatous tissue infiltration. There exist two types of frequently encountered pulmonary manifestations: (1) due to their being initially pauci-symptomatic, possibly life-threatening infectious complications are often discovered at a late stage.

View Article and Find Full Text PDF
Article Synopsis
  • This study evaluated the effectiveness and safety of the IL-5 receptor inhibitor benralizumab for treating patients with eosinophilic granulomatosis with polyangiitis (EGPA) across 28 European centers.
  • Out of 121 patients treated, complete responses increased from 12.4% at 3 months to 46.4% at 12 months, while partial responses decreased over the same period.
  • Notable improvements were seen in disease activity, as measured by the Birmingham Vasculitis Activity Score (BVAS), and a reduction in various disease manifestations, alongside better lung function.
View Article and Find Full Text PDF

Objectives: SARS-CoV-2 has impacted the detection of seasonal respiratory viruses. We retrospectively assessed the trend in the detection of 10 viruses in the COVID-19 area in 2 hospitals located in the Paris area.

Methods: All patients positive for a respiratory virus in two hospitals from September 2016 to August 2021 were retrospectively included.

View Article and Find Full Text PDF